Correlation of older age with better progression-free survival despite less aggressive resection in nonfunctioning pituitary adenomas
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Older patients with nonfunctioning pituitary adenomas (NFPAs) experience longer progression-free survival (PFS) after endonasal transsphenoidal surgery (ETS). Younger age, however, is linked to improved outcomes for male hypogonadism.
Area Of Science
- Neurosurgery
- Endocrinology
- Oncology
Background
- Nonfunctioning pituitary adenomas (NFPAs) are common tumors with variable patient ages at presentation.
- Patient age may influence long-term outcomes following surgical treatment.
- Endonasal transsphenoidal surgery (ETS) is a primary treatment modality for NFPAs.
Purpose Of The Study
- To investigate the long-term outcomes of patients with NFPAs after ETS.
- To explore the impact of patient age at presentation on outcomes, including progression-free survival (PFS) and neurological/endocrinological results.
- To stratify patients into age groups for comparative analysis.
Main Methods
- Retrospective study of 228 patients with NFPAs who underwent ETS.
- Median follow-up of 63 months.
- Age stratification into four groups (≤ 49, 50-59, 60-69, ≥ 70 years) with Kaplan-Meier and Cox proportional hazards analyses.
Main Results
- Older age was significantly associated with longer PFS (5-year PFS rates ranging from 63.0% to 88.1%, p=0.001).
- Multivariable analysis confirmed older age (HR 1.03), smaller tumor diameter (HR 0.77), and gross-total resection (HR 8.55) as predictors of longer PFS.
- Younger age was the only factor associated with postoperative improvement in male hypogonadism (HR 0.91); other endocrinological and neurological outcomes were not age-dependent.
Conclusions
- Older patients with NFPAs treated with ETS exhibit significantly longer PFS.
- Postoperative improvement in male hypogonadism is more likely in younger patients.
- Age is a critical factor influencing PFS but not all endocrinological/neurological outcomes after ETS for NFPAs.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...